bluebird bio announces new interim data from phase 1 (HGB-206) study of LentiGlobin™
bluebird bio announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease. HGB-206 is an ongoing, open-label study designed to evaluate safety and efficacy of LentiGlobin gene therapy. June 15, 2018